News

Latest news, press releases, and clinical updates from Skyhawk Therapeutics.

All Press Releases Clinical Updates Publications
CLINICAL UPDATE

Nine Month Interim Results from Phase 1 Clinical Trial of SKY-0515

Updated Phase 1 data shows sustained HTT lowering and clinical benefit through nine months of treatment with SKY-0515 in Huntington's Disease patients.

LEARN MORE →
CLINICAL UPDATE

Skyhawk Reports Positive First Results in Huntington's Patients for Oral Drug SKY-0515

SKY-0515 achieves 62% reduction in mutant HTT protein with meaningful clinical improvements in cUHDRS at 3, 6 and 9 months in the Phase 1 clinical trial.

LEARN MORE →